141 related articles for article (PubMed ID: 20937048)
1. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.
Abu-Sneineh A; Tam W; Schoeman M; Fraser R; Ruszkiewicz AR; Smith E; Drew PA; Dent J; Holloway RH
Aliment Pharmacol Ther; 2010 Oct; 32(8):1023-30. PubMed ID: 20937048
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
[TBL] [Abstract][Full Text] [Related]
3. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
4. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
5. Review article: is stringent control of gastric pH useful and practical in GERD?
Kahrilas PJ
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
Spechler SJ; Barker PN; Silberg DG
Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
[TBL] [Abstract][Full Text] [Related]
7. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; MartÃnez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
9. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
[TBL] [Abstract][Full Text] [Related]
10. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
11. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
Spechler SJ; Sharma P; Traxler B; Levine D; Falk GW
Am J Gastroenterol; 2006 Sep; 101(9):1964-71. PubMed ID: 16848802
[TBL] [Abstract][Full Text] [Related]
12. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
13. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
14. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
15. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2007 May; 39(5):415-21. PubMed ID: 17379591
[TBL] [Abstract][Full Text] [Related]
16. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
17. COX-2 mRNA is increased in oesophageal mucosal cells by a proton pump inhibitor.
Mayne GC; Watson DI; Hussey DJ
ANZ J Surg; 2012 Oct; 82(10):691-6. PubMed ID: 22758658
[TBL] [Abstract][Full Text] [Related]
18. The effect of photodynamic therapy (PDT) on oesophageal motility and acid clearance in patients with Barrett's oesophagus.
Globe J; Smythe A; Kelty CJ; Reed MW; Brown NJ; Ackroyd R
J Photochem Photobiol B; 2006 Oct; 85(1):17-22. PubMed ID: 16723253
[TBL] [Abstract][Full Text] [Related]
19. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus.
Triadafilopoulos G; Kaur B; Sood S; Traxler B; Levine D; Weston A
Aliment Pharmacol Ther; 2006 Apr; 23(7):997-1005. PubMed ID: 16573802
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitor influence on reflux in Barrett's oesophagus.
Smythe A; Troy GP; Ackroyd R; Bird NC
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):881-7. PubMed ID: 18794602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]